Physician profile

Thomas D Gary

Family Medicine · Blairsville, GA

NPI 1093891921

$194.90

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$33.55

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Hydrofera LLC $43.47 2021
Takeda Pharmaceuticals U.S.A., INC. $31.55 2020
Glaxosmithkline, LLC. $26.49 2019
Boston Scientific Corporation $19.82 2024
Merck Sharp & Dohme LLC $15.90 2020
Sunovion Pharmaceuticals INC. $15.84 2019
Astrazeneca Pharmaceuticals Lp $14.34 2019
Sanofi Pasteur INC. $13.76 2019
Pfizer INC. $13.73 2023

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Thomas D Gary

$194.90

in general payments reported 2019-2025

Years
2019-2024
Top company
Hydrofera LLC

https://glasscript.com/doctor/322259/thomas-d-gary

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.